XM无法为美国居民提供服务。

XM无法为美国居民提供服务。
B
B

BayerAG

市场新闻

Reuters - 10小时前

Bayer applies for third indication of Nubeqa in EU

Bayer applies for third indication of Nubeqa in EU BERLIN, Oct 14 (Reuters) - Bayer BAYGn.DE said on Monday that it has applied to the EU's drugs regulator for the use of Nubeqa, also known as darolutamide, in combination with androgen deprivation therapy. It said the submission to the European Medicines Agency (EMA) was based on positive results from a phase III trial that showed darolutamide plus androgen deprivation therapy (ADT) significantly reduced the risk of radiological progression or d
B
Reuters - 10小时前

Bayer Submits Application For Third Indication Of Darolutamide In EU

BRIEF-Bayer Submits Application For Third Indication Of Darolutamide In EU Oct 14 (Reuters) - BAYER AG BAYGn.DE : SUBMITS APPLICATION FOR THIRD INDICATION OF DAROLUTAMIDE IN EU IS SEEKING APPROVAL FOR USE OF DAROLUTAMIDE IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY (ADT) IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) SUBM
B
Reuters - 3天前

Bayer slips after verdict to pay $78 mln in Roundup cancer case

BUZZ-Bayer slips after verdict to pay $78 mln in Roundup cancer case ** Shares of Germany's Bayer BAYGn.DE slip 1.7% after a state court jury in Philadelphia found the company must pay $78 million in latest Roundup cancer trial ** The verdict follows previous consecutive victories for Bayer in that court ** New setback after PCB review, a local tra
B
Reuters - 4天前

US judicial panel to examine litigation finance disclosure

UPDATE 1-US judicial panel to examine litigation finance disclosure Adds comment from litigation funding group in paragraph 16 By Nate Raymond Oct 10 (Reuters) - A federal judicial rules-making panel on Thursday agreed to study whether a nationwide rule requiring disclosure of third-party litigation funding in lawsuits is necessary at the urging of major companies, business groups and Republican lawmakers .
A
B
C
G
N
P
Reuters - 4天前

US judicial panel to examine litigation finance disclosure

US judicial panel to examine litigation finance disclosure By Nate Raymond Oct 10 (Reuters) - A federal judicial rules-making panel on Thursday agreed to study whether a nationwide rule requiring disclosure of third-party litigation funding in lawsuits is necessary at the urging of major companies, business groups and Republican lawmakers . After a decade of weighing whether it should do anything to regulate the emerging field of litigation finance, the U.S.
A
B
C
G
N
P
Reuters - 4天前

Bayer must pay $78 million in latest Roundup cancer trial, jury finds

UPDATE 2-Bayer must pay $78 million in latest Roundup cancer trial, jury finds Adds statement from plaintiffs' lawyers in paragraphs 3-4, background in paragraph 10 By Brendan Pierson Oct 10 (Reuters) - Bayer BAYGn.DE must pay $78 million to a Pennsylvania man who said he got cancer from using the company's Roundup weedkiller, a state court jury in Philadelphia found on Thursday.
B
Reuters - 4天前

Bayer must pay $78 mln in latest Roundup cancer trial, jury finds

Bayer must pay $78 mln in latest Roundup cancer trial, jury finds By Brendan Pierson Oct 10 (Reuters) - Bayer BAYGn.DE must pay $78 million to a Pennsylvania man who said he got cancer from using the company's Roundup weedkiller, a state court jury in Philadelphia found on Thursday. The verdict in state court in Philadelphia follows previous consecutive victories for Bayer in that court.
B
Reuters - 5天前

Bayer falls after US court accepts PCB case for review

BUZZ -Bayer falls after US court accepts PCB case for review ** Shares in Bayer BAYGn.DE fall 7%, with an analyst pointing to new developments in a case over unit Monsanto's toxic chemicals known as PCBs as the potential reason for the move ** Bloomberg on Wednesday reported that Washington state's Supreme Court accepted to review a case against Ba
B
Reuters - 5天前

Bayer's Hot Flash Drug Elinzanetant New Drug Application Accepted by US Food And Drug Administration (FDA)

BRIEF-Bayer's Hot Flash Drug Elinzanetant New Drug Application Accepted by US Food And Drug Administration (FDA) Oct 9 (Reuters) - BAYER AG BAYGn.DE : U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTS NEW DRUG APPLICATION FOR ELINZANETANT Further company coverage: [BAYGn.DE] (Gdansk Newsroom)
B
Reuters - 6天前

Bayer And MOMA Therapeutics Enter Collaboration And License Agreement In Oncology

BRIEF-Bayer And MOMA Therapeutics Enter Collaboration And License Agreement In Oncology Oct 8 (Reuters) - BAYER AG BAYGn.DE : BAYER AND MOMA THERAPEUTICS ENTER COLLABORATION AND LICENSE AGREEMENT IN ONCOLOGY BAYER WILL BE RESPONSIBLE FOR COMPLETING FURTHER PRECLINICAL, DEVELOPMENT AND COMMERCIAL ACTIVITIES FINANCIAL TERMS OF COLLABORATION WERE NOT DISCLOSED.
B
Reuters - 1周前

US lawmaker calls for litigation funding disclosures

US lawmaker calls for litigation funding disclosures By Sara Merken Oct 7 (Reuters) - A federal lawmaker has introduced legislation that would require the disclosure of third-party funding in civil lawsuits. U.S. Republican Representative Darrell Issa of California on Friday introduced a bill that calls for parties in civil litigation to tell the court and other named parties the identity of third-party that has the right to receive payment that is contingent on the outcome of a case or group or
A
B
C
G
N
P
Reuters - 2周前

Companies ask US judiciary group to force lawsuit funding disclosures

UPDATE 1-Companies ask US judiciary group to force lawsuit funding disclosures Adds comment in paragraphs 11, 12 from funding advocate By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits.
A
B
C
G
N
P
Reuters - 2周前

Companies ask US judiciary group to force lawsuit funding disclosures

UPDATE 1-Companies ask US judiciary group to force lawsuit funding disclosures Adds comment in paragraphs 11, 12 from funding advocate By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits.
A
B
C
G
N
P
Reuters - 2周前

Companies ask US judiciary group to force lawsuit funding disclosures

Companies ask US judiciary group to force lawsuit funding disclosures By Mike Scarcella Oct 3 (Reuters) - More than 100 major companies from the technology, pharmaceutical, automotive and other sectors have urged the U.S. judiciary to adopt a nationwide rule requiring disclosure of third-party litigation funding in lawsuits. Companies including Amazon.com, Google, Cisco, Meta, Comcast, Exxon, Zurich, Eli Lilly, Bayer, Ford, Pfizer and Novartis submitted the letter on Wednesday to the federal cou
A
B
C
G
N
P
Reuters - 2周前

Bayer sees Intacta2 Xtend GMO seed covering 30% of Brazil's soybeans

Bayer sees Intacta2 Xtend GMO seed covering 30% of Brazil's soybeans SAO PAULO, Oct 3 (Reuters) - Germany's Bayer BAYGn.DE forecasts that some 30% of Brazil's soybean area will be sowed with its genetically modified biotech seed Intacta2 Xtend in the 2024/25 season, doubling the share from the previous crop, a top executive said this week. The exact share Intacta2 Xtend will reach should be clear only in some two or three weeks after expected rains allow a broad planting in Brazil's soy fields,
B
Reuters - 2周前

India's Shivalik Rasayan climbs on US FDA approval for facility

BUZZ-India's Shivalik Rasayan climbs on US FDA approval for facility ** Shares of Shivalik Rasayan SIVA.NS rise 13.1% to 639.9 rupees ** Agrochemicals and active pharma ingredients (API)-maker received U.S. FDA approval for its API facility in India's Gujarat state ** Stock eyes best day since July 3 ** SIVA down ~14% YTD; agrochemical rivals UPL U
B
Reuters - 2周前

ADNOC German deal is blueprint for Gulf takeovers

BREAKINGVIEWS-ADNOC German deal is blueprint for Gulf takeovers The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Karen Kwok LONDON, Oct 1 (Reuters Breakingviews) - Abu Dhabi National Oil Company (ADNOC) has succeeded where other Gulf buyers failed. After more than a year of negotiation, the Emirati oil giant led by Sultan al-Jaber has finally struck a deal to buy German chemical company Covestro 1COV.DE for 14.7 billion euros including debt.
B
Reuters - 2周前

Abu Dhabi's ADNOC to buy German chemicals firm Covestro for $16 bln

UPDATE 6-Abu Dhabi's ADNOC to buy German chemicals firm Covestro for $16 bln ADNOC to pay 62 euros per Covestro share, take on 3 bln in debt To buy additional 1.2 bln euros worth of new shares in Covestro Covestro shares jump 3.7% to a three-year high Deal could fuel debate over foreign takeovers of German firms Adds Covestro supervisory board's advisers in paragraph 26 By Ludwig Burger and Yousef Saba BERLIN/DUBAI Oct 1 (Reuters) - Abu Dhabi's ADNOC has struck a deal to buy German chemicals mak
B
C
G
N
O
T
U
V
Reuters - 2周前

ADNOC nears $13 billion deal to buy Germany's Covestro, WSJ reports

UPDATE 1-ADNOC nears $13 billion deal to buy Germany's Covestro, WSJ reports Adds details in paragraph 2, background from paragraph 4 onward Sept 30 (Reuters) - Abu Dhabi National Oil Company (ADNOC) is likely to announce a $13 billion-plus deal for Germany's Covestro 1COV.DE as soon as this week unless an unexpected snag emerges, the Wall Street Journal reported on Monday, citing people familiar with the matter.
B
Reuters - 2周前

Bayer To Present Seven New Analyses From HF

BRIEF-Bayer To Present Seven New Analyses From FINEARTS-HF Sept 27 (Reuters) - BAYER AG BAYGn.DE : TO PRESENT SEVEN NEW ANALYSES FROM FINEARTS-HF EXAMINING BENEFITS OF FINERENONE ACROSS A BROAD SPECTRUM OF HIGH-RISK HEART FAILURE PATIENTS Further company coverage: [BAYGn.DE] (Gdansk Newsroom)
B

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。

风险提示： 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明。